SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Hoffman Michael B

(Last) (First) (Middle)
712 FIFTH AVENUE, 51ST FLOOR

(Street)
NEW YORK NY 10019

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2013
3. Issuer Name and Ticker or Trading Symbol
Onconova Therapeutics, Inc. [ ONTX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1) 644,660 I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Convertible Preferred Stock (2) (2) Common Stock 99,350 (2) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Series C Convertible Preferred Stock (3) (3) Common Stock 140,449 (3) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Series D Convertible Preferred Stock (4) (4) Common Stock 355,528 (4) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Series E Convertible Preferred Stock (5) (5) Common Stock 634,625 (5) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Series F Convertible Preferred Stock (6) (6) Common Stock 111,227 (6) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Series F Convertible Preferred Stock (6) (6) Common Stock 109,653 (6) I By The Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust)(1)
Series G Convertible Preferred Stock (7) (7) Common Stock 229,825 (7) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Series H Convertible Preferred Stock (8) (8) Common Stock 301,290 (8) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Series I Convertible Preferred Stock (9) (9) Common Stock 1,635,514 (9) I By The Michael and Jane Hoffman 2013 Descendants Trust(1)
Stock Option (right to purchase) 03/31/2009 04/01/2016 Common Stock 18,754 $2.67 D
Stock Option (right to purchase) 10/04/2007 10/04/2017 Common Stock 56,264 $6 D
Stock Option (right to purchase) 03/17/2010 03/17/2020 Common Stock 52,513 $5.76 D
Stock Option (right to purchase) 04/18/2011 04/18/2021 Common Stock 18,754 $6.13 D
Stock Option (right to purchase) 12/05/2011 12/05/2021 Common Stock 18,754 $6.13 D
Stock Option (right to purchase) 01/01/2013 01/02/2023 Common Stock 37,509 $13.28 D
Explanation of Responses:
1. These shares are held in a trust for the benefit of the reporting person's descendents. The reporting person's spouse is a trustee of the trust.
2. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.85-for-1 basis and has no expiration date.
3. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
4. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
5. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
6. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.77-for-1 basis and has no expiration date.
7. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
8. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
9. The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
/s/ Ajay Bansal, as attorney in fact 07/24/2013
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.